PCOS to PMOS: What the New Name Means

Yes—but the precise new name matters. In 2026, a multistep international consensus process proposed polyendocrine metabolic ovarian syndrome, abbreviated PMOS, as a new name for polycystic ovary syndrome (PCOS). This is a change in terminology, not a new disease and not a reason to discard an existing diagnosis.

For now, patients may see both names. Medical records, guidelines, insurance systems and clinicians will not all change language at the same time.

Why experts wanted a different name

“Polycystic ovary syndrome” has always been imperfect. A person can meet diagnostic criteria without having polycystic-appearing ovaries, while ovarian follicles seen on ultrasound do not by themselves establish the diagnosis. The word “cysts” can also suggest a structural ovarian problem requiring removal, which is misleading.

The proposed name places three connected domains in view:

• Polyendocrine: hormonal features can include androgen excess and disrupted ovulation.
• Metabolic: insulin resistance, type 2 diabetes risk, blood-pressure and lipid abnormalities may be clinically important.
• Ovarian: irregular ovulation, menstrual changes and fertility concerns remain part of the syndrome for many patients.

The reframing is intended to make the condition’s whole-body nature easier to recognize. It does not mean every patient has every feature.

Does the diagnosis change?

Not automatically. The 2023 International Evidence-based Guideline remains the established clinical framework. In adults, diagnosis generally requires at least two of three features after other causes have been excluded: clinical or biochemical androgen excess, ovulatory dysfunction, and polycystic ovarian morphology on ultrasound. Anti-Müllerian hormone may be used instead of ultrasound in an appropriate adult diagnostic pathway, but it should not be used as a stand-alone test.

If irregular cycles and clinical androgen excess are already present, ultrasound or AMH may not be needed. Adolescents require a more cautious approach: both irregular cycles and hyperandrogenism are required, while ultrasound and AMH are not recommended for diagnosis because normal puberty can look similar.

The 2026 name consensus does not create a new test or erase those safeguards. Implementation guidance will need to explain how the terminology maps onto existing criteria.

What good care should include

Care should respond to the person’s priorities rather than the label alone. Depending on symptoms and life stage, that may include menstrual regulation, management of acne or excess hair growth, fertility support, sleep assessment, and prevention of endometrial problems when periods are very infrequent.

Metabolic health deserves attention even when fertility is not a current concern. The international guideline recommends assessment of glycaemic status and cardiovascular risk factors. It also emphasizes depression and anxiety screening, quality of life, and weight-inclusive care. PCOS is not a personal failure, and health advice should not rely on stigma.

Routine insulin measurements are not recommended for diagnosis because commonly available tests do not measure insulin resistance reliably in everyday practice. A clinician may instead assess glucose tolerance, blood pressure, cholesterol and other individual risks.

What should patients do now?

Keep existing records that use PCOS. At appointments, you can ask whether the service has adopted PMOS terminology and whether it changes anything in your care plan. The key questions remain practical: Are cycles adequately protected? Are androgen-related symptoms being addressed? Has metabolic and emotional health been assessed? Is fertility support needed now or later?

The strongest interpretation is simple: the name is changing to better reflect the biology and lived experience, but the diagnosis does not suddenly disappear.

This article is educational. PCOS/PMOS diagnosis and treatment require an individualized clinical assessment.

Still have questions or concerns?

Every woman’s health journey is different. Ask your question in the GynecHub Community, where GynecHub specialists can offer guidance.

Ask a GynecHub Specialist →

References

1. Teede HJ, et al. “Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process.” The Lancet (2026)
2. Teede HJ, et al. “Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome.” Human Reproduction (2023)